Healthcare provider profile · identity verified

Alberto Sanchez, MD

Allopathic & Osteopathic Physicians|Internal Medicine · CROWN POINT, IN · NPI 1659376259

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Alberto Sanchez, MD received $45.00 in general payments during 2025 across 1 reported records.

Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$45.00

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$45.00	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Education	$45.00	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Payment records were found, but the reported records did not identify a specific associated product for this analysis.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	39	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	27	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	724	226
Amlodipine Besylate	Amlodipine Besylate	449	122
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	409	54
Metformin Hcl	Metformin Hcl	374	113
Levothyroxine Sodium	Levothyroxine Sodium	340	92
Lisinopril	Lisinopril	337	91
Alprazolam	Alprazolam	309	44
Losartan Potassium	Losartan Potassium	266	74
Hydrochlorothiazide	Hydrochlorothiazide	219	58
Pantoprazole Sodium	Pantoprazole Sodium	204	62
Omeprazole	Omeprazole	181	55
Glimepiride	Glimepiride	157	42
Metoprolol Tartrate	Metoprolol Tartrate	148	45
Simvastatin	Simvastatin	144	43
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	138	44
Albuterol Sulfate Hfa	Albuterol Sulfate	132	43
Metoprolol Succinate	Metoprolol Succinate	128	38
Tramadol Hcl	Tramadol Hcl	112	20
Gabapentin	Gabapentin	111	43
Rosuvastatin Calcium	Rosuvastatin Calcium	109	29
Furosemide	Furosemide	107	35
Allopurinol	Allopurinol	106	29
Clopidogrel	Clopidogrel Bisulfate	101	27
Pravastatin Sodium	Pravastatin Sodium	95	29
Ozempic	Semaglutide	92	24
Sertraline Hcl	Sertraline Hcl	90	21
Tamsulosin Hcl	Tamsulosin Hcl	90	28
Eliquis	Apixaban	87	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	81	26
Zolpidem Tartrate	Zolpidem Tartrate	81	12
Fluticasone Propionate	Fluticasone Propionate	77	28
Carvedilol	Carvedilol	74	21
Famotidine	Famotidine	72	23
Potassium Chloride	Potassium Chloride	72	23
Alendronate Sodium	Alendronate Sodium	67	18
Ezetimibe	Ezetimibe	64	21
Montelukast Sodium	Montelukast Sodium	63	17
Cephalexin	Cephalexin	58	35
Naproxen	Naproxen	58	16
Breo Ellipta	Fluticasone/Vilanterol	57	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	57	21
Spironolactone	Spironolactone	57	18
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	51	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	48	17
Meloxicam	Meloxicam	48	12
Januvia	Sitagliptin Phosphate	47	suppressed
Lactulose	Lactulose	47	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	45	14
Pregabalin	Pregabalin	43	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	42	35
Trazodone Hcl	Trazodone Hcl	42	15
Duloxetine Hcl	Duloxetine Hcl	41	11
Lorazepam	Lorazepam	41	suppressed
Metformin Hcl Er	Metformin Hcl	41	12
Warfarin Sodium	Warfarin Sodium	41	suppressed
Tizanidine Hcl	Tizanidine Hcl	40	14
Jardiance	Empagliflozin	39	suppressed
Farxiga	Dapagliflozin Propanediol	37	suppressed
Citalopram Hbr	Citalopram Hydrobromide	35	11
Fentanyl	Fentanyl	34	suppressed
Methylprednisolone	Methylprednisolone	34	26
Xarelto	Rivaroxaban	34	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	33	11
Vitamin D2	Ergocalciferol (Vitamin D2)	33	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	suppressed
Diclofenac Sodium	Diclofenac Sodium	32	11
Diazepam	Diazepam	30	suppressed
Ibuprofen	Ibuprofen	30	suppressed
Memantine Hcl	Memantine Hcl	29	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	29	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	27	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	27	23
Fluoxetine Hcl	Fluoxetine Hcl	27	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	27	suppressed
Mounjaro	Tirzepatide	27	suppressed
Meclizine Hcl	Meclizine Hcl	26	11
Prednisone	Prednisone	25	suppressed
Synthroid	Levothyroxine Sodium	25	suppressed
Atenolol	Atenolol	24	suppressed
Enalapril Maleate	Enalapril Maleate	23	suppressed
Nifedipine Er	Nifedipine	22	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	21	suppressed
Clonidine Hcl	Clonidine Hcl	21	suppressed
Finasteride	Finasteride	21	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	21	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	21	suppressed
Divalproex Sodium	Divalproex Sodium	20	suppressed
Entresto	Sacubitril/Valsartan	20	suppressed
Gemfibrozil	Gemfibrozil	20	suppressed
Irbesartan	Irbesartan	20	suppressed
Klor-Con M20	Potassium Chloride	20	suppressed
Lansoprazole	Lansoprazole	20	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Klor-Con M10	Potassium Chloride	18	suppressed
Novolog Flexpen	Insulin Aspart	18	suppressed
Hydrocortisone	Hydrocortisone	17	suppressed
Ondansetron Odt	Ondansetron	17	suppressed
Tresiba Flextouch U-100	Insulin Degludec	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	16	suppressed
Digoxin	Digoxin	16	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Incruse Ellipta	Umeclidinium Bromide	15	suppressed
Repatha Sureclick	Evolocumab	15	suppressed
Telmisartan	Telmisartan	15	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	15	suppressed
Baclofen	Baclofen	14	suppressed
Loperamide	Loperamide Hcl	14	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Glipizide Er	Glipizide	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Rybelsus	Semaglutide	13	suppressed
Acetazolamide	Acetazolamide	12	suppressed
Bumetanide	Bumetanide	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Enalapril-Hydrochlorothiazide	Enalapril/Hydrochlorothiazide	12	suppressed
Glipizide	Glipizide	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Niacin Er	Niacin	12	suppressed
Prazosin Hcl	Prazosin Hcl	12	suppressed
Ramipril	Ramipril	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Celecoxib	Celecoxib	11	suppressed
Constulose	Lactulose	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Temazepam	Temazepam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$45.00 · 1 records	Lilly USA, LLC	—	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error